Table 1.
ADCC-mediating therapeutic antibodies currently FDA approved for cancer therapy.
| Antibody | Antigen | Cancer indication | Mechanisms of action |
|---|---|---|---|
| Rituximab | CD20 | CD20+ B cell NHL, CD20+ follicular NHL, CLL | ADCC, CDC, direct induction of apoptosis |
| Ofatumumab | CD20 | CLL | ADCC, CDC |
| Trastuzumab | Her2/neu | Breast cancer | ADCC, abrogation of tumor cell signaling |
| Cetuximab | EGFR | colorectal cancer, SCCHN | ADCC, abrogation of tumor cell signaling |
| Alemtuzumab* | CD52 | CLL | ADCC, CDC, direct induction of apoptosis |
NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; SCCHN, squamous cell carcinoma of the head and neck.
*Withdrawn from the market in August, 2012.